Search

Displaying results 681 - 690 of 4860 in total
  1. Drug

    Trilostane

    go.drugbank.com/drugs/DB01108
    ApprovedVet approvedWithdrawn

    It was withdrawn from the United States market in April 1994.

  2. Drug

    Pirfenidone

    go.drugbank.com/drugs/DB04951
    ApprovedInvestigational

    [A251370] It is an antifibrotic agent with anti-inflammatory and antioxidant properties [A251370] that is used to treat idiopathic pulmonary fibrosis (IPF),[L26801] which is a chronic, progressive form

  3. Drug

    Protein S human

    go.drugbank.com/drugs/DB13149
    ApprovedInvestigational

    It serves as a negative feedback mechanism in the coagulation cascade.

  4. Drug

    Dolutegravir

    go.drugbank.com/drugs/DB08930
    ApprovedInvestigational

    [A7514] The effect of this drug has no homology in human host cells, which gives it excellent tolerability and minimal toxicity.

  5. Drug

    Icosapent

    go.drugbank.com/drugs/DB00159
    ApprovedInvestigationalNutraceutical

    It serves as the precursor for the prostaglandin-3 and thromboxane-3 families.

    Mixtures: BP Vit 3
  6. Drug

    Travoprost

    go.drugbank.com/drugs/DB00287
    ApprovedInvestigational

    It is used to decrease intraocular pressure in open-angle glaucoma and ocular hypertension.

  7. Drug

    Chlorphenesin

    go.drugbank.com/drugs/DB00856
    Approved

    Mixtures: Puricia Sanitizing Wipes (Mint)
  8. Drug

    Segesterone acetate

    go.drugbank.com/drugs/DB14583
    Approved

    It mediates progestational activity 100 times higher than that of [progesterone] [A37092]. … It is commonly sold under the brand names Nestorone and Elcometrine and serves as an active component in hormonal contraceptives.

  9. Drug

    D-Methionine

    go.drugbank.com/drugs/DB02893
    Approved

    Mixtures: Nutrineal PD4 mit 1,1 % Aminosäuren - Peritonealdialyselösung
  10. Drug

    Antihemophilic factor (recombinant), PEGylated

    go.drugbank.com/drugs/DB09329
    ApprovedInvestigational

    It has been created to increase the half-life of factor VIII, which decreases dose frequency and decreases the occurrence of bleeding events [A32067], [A32069], [FDA label].